Current Roles

Employees:
521
Revenue:
$307.6M
About
Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. Biohaven obtained licenses from Yale University School of Medicine and Massachusetts General Hospital regarding intellectual property relating to the use of certain glutamate modulating agents in the treatment of neuropsychiatric disorders. The mission of the company is to exploit advances over the past decade in the understanding of glutamate mechanisms involved in a variety of diseases. The company's first drug candidate is being developed for orphan neurological disorders as well as treatment-resistant anxiety and depression. Biohaven has assembled a team of experts who have extensive experience in the development of therapeutic agents in this area and also comprise the originators at Yale University who discovered the therapeutic potential of glutamate modulation in anxiety and depression. Team members have designed and executed successful development programs testing a variety of agents in affective disorders, leading to first-cycle FDA approvals and successful commercialization.
Biohaven Pharmaceuticals Address
215 Church Street
New Haven, CT
United States
Biohaven Pharmaceuticals Email
Biohaven Pharmaceuticals Phone Numbers
203-784-3702

Past Companies

Biohaven LimitedCEO and Chairman Board of Directors
Yale School of MedicineAssociate Clinical Professor
Yale School of MedicineAssistant Clinical Professor

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.